Usability and Preference Evaluation of the Somapacitan Pen-Injector and Lonapegsomatropin Autoinjector: Results of a US-Based Simulated-Use Study with Adolescent Patients and Caregivers.

PURPOSE

To compare the preference and ease of use/learning how to use, of the somapacitan (Sogroya) pen-injector and the lonapegsomatropin (Skytrofa) autoinjector among adolescents with growth-related disorders (GRDs) and caregivers of individuals with GRDs.

PATIENTS AND METHODS

This was a randomized, open-label, multicenter, usability-based preference and handling study with a crossover design. Participants recruited were adolescents aged 10-17 years with a GRD, able to self-administer growth hormone (GH) or perform some of substeps required; and caregivers aged ≥18 years and regular care providers for individuals with GRDs. Participants completed a series of simulated injections using both devices and completed a Device Handling and Preference Assessment Questionnaire (DHPAQ). Training time and time to prepare and inject with each device were also evaluated.

RESULTS

Seventy participants were recruited overall; 35 in each of the adolescent and caregiver groups. Most (78.6%) participants preferred the somapacitan device to the lonapegsomatropin device (95% confidence interval [CI] 67.1-87.5). The lonapegsomatropin device was preferred by 14.3% of participants, and 7.1% indicated no preference. Most participants indicated that somapacitan device was easy to use (97.1% [95% CI 90.1-99.7]) and learn how to use (95.7% [95% CI 88.0-99.1]). The same was reported for the lonapegsomatropin device by 57.1% (95% CI 44.8-68.9) and 54.3% (95% CI 41.9-66.3%) of participants, respectively. Average time taken to complete training for the somapacitan device and to prepare and inject was shorter than that for the lonapegsomatropin device (5.9 min vs 24.0 min, and 0.9 vs 10.6 min, respectively).

CONCLUSION

The somapacitan device was preferred over the lonapegsomatropin device among adolescents with GRDs and caregivers of individuals with GRDs. Individuals receiving GH treatment via the somapacitan device may be more likely to have higher treatment adherence than those using the lonapegsomatropin device.